SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                          Date of Report: June 24, 1999



                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)



                         Commission File Number: 0-19131




                  Delaware                            52-1555759
          (State of Incorporation)                  (I.R.S. Employer
                                                    Identification No.)



                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)


        Registrant's telephone number, including area code (301) 417-0770


                  No Exhibits are being filed with this report.


CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.



<PAGE>


MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated June 24, 1999:

FOR IMMEDIATE RELEASE

Contacts:
William C. Roberts
Investor and Media Relations
MedImmune, Inc.
301-417-0770 x358


http://www.medimmune.com


                 MEDIMMUNE ANNOUNCES NEW EXECUTIVE APPOINTMENTS

Gaithersburg, MD, June 24, 1999 -- MedImmune, Inc. (Nasdaq:MEDI) today announced
four new  appointments  to new  positions  within the Company.  Randall  Turner,
formerly  Vice  President,   Pharmaceutical/Biotech   with  Black  &  Veach,  an
international  engineering  consulting  firm,  has  been  appointed  to the  new
position of Vice President, Engineering & Facilities, reporting to Mr. Melvin D.
Booth,  President  and Chief  Operating  Officer of MedImmune.  Also,  Bernardus
Machielse,  formerly Vice President,  Quality Assurance and Quality Control with
XOMA  Corporation,  a  biotechnology  company,  has  been  appointed  to the new
position  of Vice  President,  Quality.  He will  report to Bogdan  Dziurzynski,
Senior Vice President,  Regulatory  Affairs and Quality  Assurance at MedImmune.
Additionally,  Scott Koenig, M.D., Ph.D., previously Vice President of Research,
has been promoted to the position of Senior Vice President of Research. Finally,
James  F.  Young,  Ph.D.,   previously  Senior  Vice  President,   Research  and
Development,  has been  promoted to the  position of Executive  Vice  President,
Research and Development.

"The addition of Mr. Turner will allow MedImmune to  successfully  carry out our
long-term plans of corporate growth and to support our commercial  manufacturing
capabilities,"  commented Melvin D. Booth, President and Chief Operating Officer
of MedImmune. "Additionally, Mr. Machielse will enhance the articulation between
Quality  Control,  Quality  Assurance and  validation in order to strengthen our
focus on quality and GMP compliance. We welcome them both to MedImmune."

As Vice  President of  Engineering & Facilities,  Mr. Turner will be responsible
for all major engineering projects in the Frederick and Gaithersburg facilities,
the  engineering  oversight of the  Gaithersburg  Manufacturing  and Development
Facility and corporate engineering  activities such as expansion and renovation.
Prior to joining  MedImmune,  Mr.  Turner  served  from 1995 to 1998 as the Vice
President of  Pharmaceutical/Biotech  at Black and Veach. He was responsible for
overseeing process engineering,  detailed design,  construction,  validation and
start-up  assistance  on  facilities  regulated  by United  States and  European
authorities.  His  responsibilities  recently  included  the project  design and
construction  of two new  facilities for products  launched for Pfizer,  and the
design of a manufacturing  facility for  Schering-Plough.  From 1989 to 1995, as
the  Director of Corporate  Manufacturing  and  Engineering  Services for Sanofi
Inc.,  Mr.  Turner  was  responsible  for all  engineering  activities  in North
America,  South  America,  Australia and the Pacific Rim. From 1977 to 1989, Mr.
Turner  worked for Pfizer,  Inc.,  where he  ultimately  became the  Director of
Engineering.  Prior  to his  term at  Pfizer,  Mr.  Turner  was a Field  Service
Engineer  for General  Electric.  Mr.  Turner  holds a Bachelor of Science and a
Masters of Science in mechanical  engineering  from the  University of Missouri,
Columbia, Missouri.

As Vice  President,  Quality,  Mr.  Machielse  will be  responsible  for quality
assurance and documentation,  quality control, validation, calibration, clinical
support testing and GMP compliance at the Gaithersburg and Frederick facilities.
Prior to joining MedImmune,  Mr. Machielse served from 1996 through 1999 as Vice
President,  Quality  Assurance and Quality Control at XOMA  Corporation.  He was
responsible for the functions of Quality  Control,  Quality  Assurance,  Quality
Engineering,  Compliance  and  Document  Control in both the  Berkeley and Santa
Monica facilities. From 1995 to 1996, he was the Director of Quality at XOMA and
was responsible for the Quality Assurance and Quality Control groups.  From 1987
to 1995,  Mr.  Machielse  held  various  titles at Centocor  BV, a wholly  owned
subsidiary of Centocor,  Inc. in The  Netherlands,  culminating  in 1993 when he
became the  Associate  Director of Quality  Control.  In this  position,  he was
responsible for managing various Quality Control groups including  microbiology,
stability,  and  routine  testing.  Additionally,  he was  responsible  for  the
analytical  development group and the laboratory automation group. Mr. Machielse
holds a  Bachelors  degree in  Medical  Biology  and a  Masters  of  Science  in
Biochemistry from the University of Utrecht, Utrecht, The Netherlands.

As Senior Vice President of Research,  Dr. Koenig will continue his focus on new
research  initiative   identification  and  oversee  all  preclinical  discovery
efforts,  including  project design,  execution and management.  Dr. Koenig will
continue to report to James Young,  Ph.D. Dr. Koenig joined MedImmune in 1990 as
the Director of Immunology, and was promoted in 1994 to the position of Director
of Research. In 1995, Dr. Koenig became the Vice President of Research. Prior to
joining  MedImmune,  Dr.  Koenig  worked for the National  Institutes of Health,
National  Institute of Allergy and Infectious  Diseases first as a Medical Staff
Fellow from 1984 to 1987,  and then as a Senior  Staff Fellow from 1987 to 1990.
Dr. Koenig holds a medical  degree from the  University of Texas Health  Science
Center at Houston,  a doctorate in Immunology from Cornell  University  Graduate
School  of  Medical  Sciences,  and a  Bachelor  of  Arts  degree  from  Cornell
University.  He is a  board-certified  specialist in Allergy and  Immunology and
Internal Medicine.

As Executive Vice President of Research and Development, Dr. Young will continue
to be responsible for the oversight of all research and  development  activities
and  identification  of new  strategic  research  initiatives.  Dr.  Young  will
continue to report to Wayne T.  Hockmeyer,  Ph.D. Dr. Young joined  MedImmune in
March 1989 as Vice  President of Research and  Development,  and was promoted in
1995 to Senior Vice President of Research and  Development.  Prior to his tenure
at MedImmune,  Dr. Young held various  positions from 1983 to 1989 at SmithKline
and French  Laboratories,  Inc., where he ultimately  became the Director of the
Department  of  Molecular  Genetics.  Prior to 1983,  Dr.  Young  was  Assistant
Professor of Microbiology at Mount Sinai School of Medicine,  New York, N.Y. Dr.
Young holds a doctorate in  microbiology  and immunology  from Baylor College of
Medicine,  Houston,  Texas and a  Bachelor  of  Science  degree  from  Villanova
University.

MedImmune, a biotechnology company located in Gaithersburg, Maryland, is focused
on developing and marketing products that address medical needs in areas such as
infectious disease,  transplantation medicine,  autoimmune disorders and cancer.
The Company  currently  markets  Synagis  (palivizumab),  RespiGam  (Respiratory
Syncytial   Virus   Immune   Globulin   Intravenous   (Human)),    and   CytoGam
(Cytomegalovirus Immune Globulin Intravenous (Human)) through its hospital-based
sales force and has five new product candidates in clinical trials.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a  number  of  factors,  including  risks  and  uncertainties  discussed  in the
Company's filings with the U.S. Securities and Exchange Commission.

                                      ####



(REGISTRANT)      MEDIMMUNE, INC.





BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, Vice Chairman and Chief Financial Officer
(DATE)            June 24, 1999
[{"type": "8-K", "sequence": "1", "description": "MEDIMMUNE ANNOUNCES NEW EXECUTIVE APPOINTMENTS", "secsgml_size_bytes": 9319}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14657", "film-number": "99651639"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                          Date of Report: June 24, 1999

                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)

                         Commission File Number: 0-19131

                  Delaware                            52-1555759
          (State of Incorporation)                  (I.R.S. Employer
                                                    Identification No.)

                35 West Watkins Mill Road, Gaithersburg, MD 20878
                (Address of principal executive office (Zip Code)

        Registrant's telephone number, including area code (301) 417-0770

                  No Exhibits are being filed with this report.

CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.
MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune,  Inc.  reported  the  information  contained in the  following  press
release dated June 24, 1999:

FOR IMMEDIATE RELEASE

Contacts:
William C. Roberts
Investor and Media Relations
MedImmune, Inc.
301-417-0770 x358

http://www.medimmune.com

                 MEDIMMUNE ANNOUNCES NEW EXECUTIVE APPOINTMENTS

Gaithersburg, MD, June 24, 1999 -- MedImmune, Inc. (Nasdaq:MEDI) today announced
four new  appointments  to new  positions  within the Company.  Randall  Turner,
formerly  Vice  President,   Pharmaceutical/Biotech   with  Black  &  Veach,  an
international  engineering  consulting  firm,  has  been  appointed  to the  new
position of Vice President, Engineering & Facilities, reporting to Mr. Melvin D.
Booth,  President  and Chief  Operating  Officer of MedImmune.  Also,  Bernardus
Machielse,  formerly Vice President,  Quality Assurance and Quality Control with
XOMA  Corporation,  a  biotechnology  company,  has  been  appointed  to the new
position  of Vice  President,  Quality.  He will  report to Bogdan  Dziurzynski,
Senior Vice President,  Regulatory  Affairs and Quality  Assurance at MedImmune.
Additionally,  Scott Koenig, M.D., Ph.D., previously Vice President of Research,
has been promoted to the position of Senior Vice President of Research. Finally,
James  F.  Young,  Ph.D.,   previously  Senior  Vice  President,   Research  and
Development,  has been  promoted to the  position of Executive  Vice  President,
Research and Development.

"The addition of Mr. Turner will allow MedImmune to  successfully  carry out our
long-term plans of corporate growth and to support our commercial  manufacturing
capabilities,"  commented Melvin D. Booth, President and Chief Operating Officer
of MedImmune. "Additionally, Mr. Machielse will enhance the articulation between
Quality  Control,  Quality  Assurance and  validation in order to strengthen our
focus on quality and GMP compliance. We welcome them both to MedImmune."

As Vice  President of  Engineering & Facilities,  Mr. Turner will be responsible
for all major engineering projects in the Frederick and Gaithersburg facilities,
the  engineering  oversight of the  Gaithersburg  Manufacturing  and Development
Facility and corporate engineering  activities such as expansion and renovation.
Prior to joining  MedImmune,  Mr.  Turner  served  from 1995 to 1998 as the Vice
President of  Pharmaceutical/Biotech  at Black and Veach. He was responsible for
overseeing process engineering,  detailed design,  construction,  validation and
start-up  assistance  on  facilities  regulated  by United  States and  European
authorities.  His  responsibilities  recently  included  the project  design and
construction  of two new  facilities for products  launched for Pfizer,  and the
design of a manufacturing  facility for  Schering-Plough.  From 1989 to 1995, as
the  Director of Corporate  Manufacturing  and  Engineering  Services for Sanofi
Inc.,  Mr.  Turner  was  responsible  for all  engineering  activities  in North
America,  South  America,  Australia and the Pacific Rim. From 1977 to 1989, Mr.
Turner  worked for Pfizer,  Inc.,  where he  ultimately  became the  Director of
Engineering.  Prior  to his  term at  Pfizer,  Mr.  Turner  was a Field  Service
Engineer  for General  Electric.  Mr.  Turner  holds a Bachelor of Science and a
Masters of Science in mechanical  engineering  from the  University of Missouri,
Columbia, Missouri.

As Vice  President,  Quality,  Mr.  Machielse  will be  responsible  for quality
assurance and documentation,  quality control, validation, calibration, clinical
support testing and GMP compliance at the Gaithersburg and Frederick facilities.
Prior to joining MedImmune,  Mr. Machielse served from 1996 through 1999 as Vice
President,  Quality  Assurance and Quality Control at XOMA  Corporation.  He was
responsible for the functions of Quality  Control,  Quality  Assurance,  Quality
Engineering,  Compliance  and  Document  Control in both the  Berkeley and Santa
Monica facilities. From 1995 to 1996, he was the Director of Quality at XOMA and
was responsible for the Quality Assurance and Quality Control groups.  From 1987
to 1995,  Mr.  Machielse  held  various  titles at Centocor  BV, a wholly  owned
subsidiary of Centocor,  Inc. in The  Netherlands,  culminating  in 1993 when he
became the  Associate  Director of Quality  Control.  In this  position,  he was
responsible for managing various Quality Control groups including  microbiology,
stability,  and  routine  testing.  Additionally,  he was  responsible  for  the
analytical  development group and the laboratory automation group. Mr. Machielse
holds a  Bachelors  degree in  Medical  Biology  and a  Masters  of  Science  in
Biochemistry from the University of Utrecht, Utrecht, The Netherlands.

As Senior Vice President of Research,  Dr. Koenig will continue his focus on new
research  initiative   identification  and  oversee  all  preclinical  discovery
efforts,  including  project design,  execution and management.  Dr. Koenig will
continue to report to James Young,  Ph.D. Dr. Koenig joined MedImmune in 1990 as
the Director of Immunology, and was promoted in 1994 to the position of Director
of Research. In 1995, Dr. Koenig became the Vice President of Research. Prior to
joining  MedImmune,  Dr.  Koenig  worked for the National  Institutes of Health,
National  Institute of Allergy and Infectious  Diseases first as a Medical Staff
Fellow from 1984 to 1987,  and then as a Senior  Staff Fellow from 1987 to 1990.
Dr. Koenig holds a medical  degree from the  University of Texas Health  Science
Center at Houston,  a doctorate in Immunology from Cornell  University  Graduate
School  of  Medical  Sciences,  and a  Bachelor  of  Arts  degree  from  Cornell
University.  He is a  board-certified  specialist in Allergy and  Immunology and
Internal Medicine.

As Executive Vice President of Research and Development, Dr. Young will continue
to be responsible for the oversight of all research and  development  activities
and  identification  of new  strategic  research  initiatives.  Dr.  Young  will
continue to report to Wayne T.  Hockmeyer,  Ph.D. Dr. Young joined  MedImmune in
March 1989 as Vice  President of Research and  Development,  and was promoted in
1995 to Senior Vice President of Research and  Development.  Prior to his tenure
at MedImmune,  Dr. Young held various  positions from 1983 to 1989 at SmithKline
and French  Laboratories,  Inc., where he ultimately  became the Director of the
Department  of  Molecular  Genetics.  Prior to 1983,  Dr.  Young  was  Assistant
Professor of Microbiology at Mount Sinai School of Medicine,  New York, N.Y. Dr.
Young holds a doctorate in  microbiology  and immunology  from Baylor College of
Medicine,  Houston,  Texas and a  Bachelor  of  Science  degree  from  Villanova
University.

MedImmune, a biotechnology company located in Gaithersburg, Maryland, is focused
on developing and marketing products that address medical needs in areas such as
infectious disease,  transplantation medicine,  autoimmune disorders and cancer.
The Company  currently  markets  Synagis  (palivizumab),  RespiGam  (Respiratory
Syncytial   Virus   Immune   Globulin   Intravenous   (Human)),    and   CytoGam
(Cytomegalovirus Immune Globulin Intravenous (Human)) through its hospital-based
sales force and has five new product candidates in clinical trials.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a  number  of  factors,  including  risks  and  uncertainties  discussed  in the
Company's filings with the U.S. Securities and Exchange Commission.

                                      ####

(REGISTRANT)      MEDIMMUNE, INC.

BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, Vice Chairman and Chief Financial Officer
(DATE)            June 24, 1999